Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Inflammopharmacology · 2024
DOI: 10.1007/s10787-024-01508-w ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Inflammopharmacology, 2024. Verfasst von Mahmoud E Kamal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt. mahmoud-essam@eru.edu.eg. Hauptthemen laut MEDLINE: Infliximab, Adalimumab. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Egyptian Russian University.
Abstract (Originalsprache)
Introduction
Inflammatory bowel disease (IBD), consists of two primary types: Ulcerative Colitis (UC) and Crohn’s Disease (CD). Infliximab (IFX) and Adalimumab (ADA) are frequently utilized in the management of moderate to severe cases of IBD.
Aim
This study aimed to assess the efficacy and safety of IFX and ADA in individuals diagnosed with moderate to severe IBD.
Method
This study is a prospective open-labeled randomized parallel study that included moderate to severe IBD patients treated with either IFX or ADA. A total of 56 patients participated, with 34 patients received IFX and 22 patients received ADA. Various measures, including Crohn’s Disease Activity Index (CDAI), Mayo Score/ Disease Activity Index (DAI), and C-reactive protein (CRP) levels, were taken at baseline and week 14 to assess the efficacy of the treatments. In addition, the levels of drugs and sTREM-1 were measured at 14 weeks. Patient safety was monitored throughout the study period.
Results
In the group received IFX, there was a notable decrease in CDAI ( P = 0.045), DAI ( P = 0.026), and CRP ( P = 0.023 for CD, and P = 0.021 for UC) levels. In addition, the group received ADA experienced a significant reduction in CDAI ( P = 0.001), DAI ( P = 0.032), and CRP ( P < 0.018 for CD and P = 0.003 for UC) levels. Responders had higher drug concentrations than non-responders, notably IFX concentration was higher in responders with CD ( P = 0.001) and UC ( P < 0.001). ADA concentration was higher in UC ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt. mahmoud-essam@eru.edu.eg.
- Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
- Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt.
- Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Biochemistry Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
- Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
ORCID-Profile: Rehab H Werida
Förderung
- Egyptian Russian University
Zitieren
APA
Kamal, M. E., Werida, R. H., Radwan, M. A., Askar, S. R., Omran, G. A., El-Mohamdy, M. A., & Hagag, R. S. (2024). Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01508-w
Vancouver
Kamal ME, Werida RH, Radwan MA, Askar SR, Omran GA, El-Mohamdy MA, et al. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. Inflammopharmacology. 2024. doi:10.1007/s10787-024-01508-w
BibTeX
@article{Kamal2024,
author = {Kamal, Mahmoud E and Werida, Rehab H and Radwan, Mahasen A and Askar, Safaa R and Omran, Gamal A and El-Mohamdy, Marwa A and Hagag, Radwa S},
title = {Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients},
journal = {Inflammopharmacology},
year = {2024},
doi = {10.1007/s10787-024-01508-w}
}
EUVIMED